by kati.sallinen@desentum.fi | Mar 12, 2026 | News
Desentum is developing novel allergen immunotherapy designed to make treatment faster, more effective, and safer. Finnish private investors and family offices invested €8 million in an exceptionally rapid share issue. The offering was organized by a Finnish growth...
by kati.sallinen@desentum.fi | Feb 18, 2026 | News
A scientific paper about the mechanism of peanut allergy has been published in the renowned journal Allergy by the research group of the University of Eastern Finland and Desentum. The main peanut allergen Ara h 2 was crystallized together with an IgE antibody Fab...
by kati.sallinen@desentum.fi | Jan 21, 2026 | News
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, today announced that its Phase 2 clinical study evaluating DM‑101PX for the treatment of birch pollen allergy has completed enrolment. 97 participants have been randomised...
by kati.sallinen@desentum.fi | Jan 13, 2026 | News
Desentum Oy:n osakkeenomistajat kutsutaan yhtiön ylimääräiseen yhtiökokoukseen, joka pidetään 3.2.2026 klo 13.00 alkaen osoitteessa Technopolis, Innopoli 2, Tekniikantie 14, 02150 Espoo. Kokoushuone: Edison 2. Yhtiökokousta voi seurata Teams-etäyhteyden...
by kati.sallinen@desentum.fi | Dec 2, 2025 | News
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, announced today that the first trial participants have received their first doses in a Phase 2 clinical study, BASIT, evaluating DM-101PX for treatment of birch pollen allergy....
